Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Nielsen, Kaspar R ^a   Steffensen, Rudi ^a   Boegsted, Martin ^a   Baech, John ^a   Lundbye Christensen, Soeren ^a   Hetland, Merete L ^b   Krintel, Sophine B ^b   Johnsen, Hans E ^a   Nyegaard, Mette ^a   Johansen, Julia S ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHI3L1 PROTEIN; CHITINASE; GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; YKL 40 PROTEIN; ADIPOCYTOKINE; AUTOANTIGEN; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; ALLELE; ARTICLE; CHROMOSOME 1Q; CHROMOSOME 1Q32.1; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; DENMARK; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROMOTER REGION; RISK FACTOR;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; DENMARK; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LECTINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; YOUNG ADULT;

EID: 79959673903     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3391     Document Type: Article

References (54)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672. 10.1016/S0140-6736(09)60008-8, 19157532.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
3. Oliver JE, Worthington J, Silman A. Genetic epidemiology of rheumatoid arthritis. Curr Opin Rheumatol 2006, 18:141-146. 10.1097/01.bor.0000209425.84775.23, 16462519.
4. Robert M, Plengea B. Recent progress in rheumatoid arthritis genetics:one step towards improved patient care. Curr Opin Rheumatol 2009, 21:262-271. 10.1097/BOR.0b013e32832a2e2d, 19365266.
5. Karlson EW. Associations between HLA, PTPN22, CTLA4 genotypes and RA phenotypes of autoantibody status, age at diagnosis, and erosions in a large cohort study. Ann Rheum Dis 2008, 67:358-363. 2945890, 17666451.
6. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage-differentiation. Genomics 1997, 43:221-225. 10.1006/geno.1997.4778, 9244440.
7. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992, 7:501-512.
8. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006, 53:172-209.
9. Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammationassociated carcinogenic changes of epithelial cells. World J Gastroenterol 2009, 15:5249-5259. 10.3748/wjg.15.5249, 2776850, 19908331.
10. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker?. Future Oncol 2009, 5:1065-1082. 10.2217/fon.09.66, 19792974.
11. Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, Meijerink JH, Elewaut D, de Keyser F, Veys E, Boots AM. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997, 40:1115-1125. 10.1002/art.1780400616, 9182922.
12. Cope AP, Patel SD, Hall F, Congia M, Hubers HA, Verheijden GF, Boots AM, Menon R, Trucco M, Rijnders AW, Sønderstrup G. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum 1999, 42:1497-1507. 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#, 10403279.
13. Vos K, Miltenburg AM, van Meijgaarden KE, van den Heuvel M, Elferink DG, van Galen PJ, van Hogezand RA, van Vliet-Daskalopoulou E, Ottenhoff TH, Breedveld FC, Boots AM, de Vries RR. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology 2000, 39:1326-1331. 10.1093/rheumatology/39.12.1326, 11136874.
14. Patil NS, Hall FC, Drover S, Spurrell DR, Bos E, Cope AP, Sonderstrup G, Mellins ED. Autoantigenic HCgp39 epitopes are presented by the HLADM-dependent presentation pathway in human B cells. J Immunol 2001, 166:33-41.
15. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol 2003, 30:449-454.
16. Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920. 10.1016/S0168-8278(00)80095-1, 10898311.
17. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, Kouroumalis EA. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003, 18:254-259.
18. Harvey S, Whaley J, Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol 2000, 29:391-393. 10.1080/030097400447606, 11132209.
19. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol 2001, 19:655-660.
20. Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 2010, 56:1580-1591. 10.1373/clinchem.2010.146530, 20798353.
21. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010, 68:672-680. 10.1002/ana.22220, 21031582.
22. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C, . CLARICOR Trial Group High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009, 30:1066-1072. 10.1093/eurheartj/ehp049, 19270316, CLARICOR Trial Group.
23. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R, Taudorf S, Lindegaard B, Pedersen BK. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008, 57:3078-3082. 10.2337/db08-0182, 2570404, 18650368.
24. Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008, 181:5167-5173.
25. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, . HALT-C Trial Group Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409. 10.1136/gut.2010.207423, 20675691, HALT-C Trial Group.
26. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357:2016-2027. 10.1056/NEJMoa073600, 18003958.
27. Recklies AD, Ling H, White C. Inflammatory cytokines induce production of chitinase-3-like protein 1 by articular chondrocytes. J Biol Chem 2005, 280:41213-41221. 10.1074/jbc.M510146200, 16234240.
28. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004, 380:651-659. 10.1042/BJ20040099, 1224214, 15015934, 15015934.
29. Mizoguchi E, Mizoguchi A. Is the sugar always sweet in intestinal inflammation?. Immunol Res 2007, 37:47-60. 10.1007/BF02686089, 17496346.
30. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine 2011, 55:152-155. 10.1016/j.cyto.2011.03.014, 21478032.
31. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B mediated signalling pathways. Biochem J 2002, 365:119-126. 10.1042/BJ20020075, 1222662, 12071845.
32. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury. Ann Rev Physiol 2011, 73:479-501.
33. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011, 10:742-751. 10.1158/1535-7163.MCT-10-0868, 21357475.
34. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B, Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011, 286:15332-15343. 10.1074/jbc.M110.212514, 21385870.
35. Rehli M, Niller HH, Ammon C. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067. 10.1074/jbc.M306792200, 12933821.
36. Zhao X, Tang R, Gao B. Functional variants in the promoter region of chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007, 80:12-18. 10.1086/510438, 1785314, 17160890.
37. Rathcke CN, Holmkvist J, Jørgensen T, Borch-Johnsen K, Hansen T, Pedersen OB, Vestergaard H. Variation in CHI3L1 in relation to type 2 diabetes and related quantitative traits. Plos One 2009, 4:e5469. 10.1371/journal.pone.0005469, 2674946, 19421404.
38. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM. CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 2007, 101:1563-1571. 10.1016/j.rmed.2006.12.006, 17236752.
39. Rathcke CN, Holmkvist J, Husmoen LL, Hansen T, Pedersen O, Vestergaard H, Linneberg A. Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 danish adults. PLoS One 2009, 4:e6106. 10.1371/journal.pone.0006106, 2699472, 19568425.
40. Sohn MH, Lee JH. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009, 179:449-456. 10.1164/rccm.200809-1422OC, 19106306.
41. Ohi K, Hashimoto R, Yasuda Y. The chitinase 3-like 1 gene and schizophrenia: evidence from a multi-center case-control study and meta-analysis. Schizophr Res 2010, 116:126-132. 10.1016/j.schres.2009.12.002, 20051317.
42. Yang MS, Morris DW, Donohoe G, Kenny EO, Dushalaine CT, Schwaiger S, Nangle JM, Clarke S, Scully P, Quinn J, Meagher D, Baldwin P, Crumlish NO, Callaghan E, Waddington JL, Gill M, Corvin A. Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism. Biol Psychiatry 2008, 64:98-103. 10.1016/j.biopsych.2007.12.012, 18281018.
43. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009, 50:370-376. 10.1016/j.jhep.2008.09.016, 19070929.
44. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF, Nicolae DL, Elias JA, Chupp GL. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008, 358:1682-1691. 10.1056/NEJMoa0708801, 2629486, 18403759.
45. Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immun 2009, 9:401-408.
46. Srivastava SK, Antal P, Gál J. Lack of evidence for association of two functional SNPs of CHI3L1 gene (HC-gp39) with rheumatoid arthritis. Rheumatol Int 2011, 31:1003-1007. 10.1007/s00296-010-1396-3, 20300754, 20300754.
47. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
48. Hetland ML. DANBIO - powerful research database and electronic patient record. Rheumatology 2011, 50:69-77. 10.1093/rheumatology/keq309, 21148154.
49. Harvey S, Weisman MO, Dell J. Chondrex: new marker of joint disease. Clin Chem 1998, 44:509-516.
50. Yong Y, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Research 2005, 15:97-98. 10.1038/sj.cr.7290272, 15740637.
51. R Development Core Team R A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria, ISBN 3-900 2004, R Development Core Team., http://www.r-project.org
52. Harrell F. Regression Modeling Strategies 2001, New York: Springer Verlag.
53. Johansen JS, Pedersen AN, Schroll M. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008, 151:260-266. 2276948, 18070151.
54. Johansen JS, Bojesen SE, Mylin AK. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009, 27:572-578. 19075264, 19075264 .